Resident News
Other news
Syndesi Therapeutics announces initiation of Phase I study of novel SV2A modulator, SDI‐118, in development for the treatment of cognitive impairment.
Read full storyOther news
Syndesi Therapeutics Awarded Non-dilutive Funding of up to €3.2M for Development of its Lead Program, SDI-118, Aimed at Treating Cognitive Impairment
Read full storyOther news
Calypso Biotech BV secures 20 Million EUR in Series A Financing to Develop Anti-IL-15 Therapeutic Antibody for Autoimmune Diseases
Read full storyOther news
Genome Biologics wins prestigious Horizon 2020 EU Phase 2 grant award
Read full storyIn the media
Johnson & Johnson Opens JLABS @ NYC
Read full storyOther news
Riding the Start-Up Roller Coaster: What It's Really Like to Be a Healthcare Entrepreneur
Read full storyOther news
IDEAYA Biosciences raised a $94M crossover Series B financing to develop next generation biomarker-enabled synthetic lethality therapies.
Read full storyOther news
Sirenas LLC. annouced today they have entered a muti-target research collaboration agreement with Bristol-Myers Squibb to deploy a drug discovery platform against undisclosed challenging therapeutic targets
Read full storyOther news
Nanovista Inc. closes $2.3 million seed round to advance its multimodal visualization agent towards clinical trials
Read full storyOther news
Symic Bio Completes the MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Knee Osteoarthritis
Read full storyOther news
Imago BioSciences Receives FDA Approval of IND Application for the Treatment of Myeloid Malignancies
Read full storyOther news
Advanced Proteome Therapeutics Corporation (APC), a therapeutics discovery and development company, and ImmunoBiochem Corporation, announced they are entering into a Collaboration and Option agreement to develop superior antibody-drug conjugates
Read full storyOther news
JLABS TMC Company finds Growth in Shrinking Cells
Read full storyOther news